source
- ArriVent shares tumble as lung cancer trial of furmonertinib misses primary goalArriVent BioPharma reported that its late-stage study of furmonertinib in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer did not achieve its primary endpoint. The trial, w…
- UK regulator adopts AI framework for medical devices and launches third AI Airlock phaseThe Medicines and Healthcare products Regulatory Agency (MHRA) announced that the UK government has adopted a set of recommendations on the use of artificial intelligence in medical devices. These…